Gabapentin
Product Images NDC 67046-341

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 67046-341). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

G6 (Gabapentin 600mg 341)

Gabapentin 600 mg tablets label with a quantity of 30 tablets. The label includes storage instructions, barcode, and states the product is prescription only with an expiration date of 12/31/2020. It is packaged by Contract Pharmacy Services-PA located in Warrington, PA. The label also advises to see the package insert for full prescribing information.*

FDA Label Image

G8 (Gabapentin 800mg 413)

Gabapentin 800 mg tablet label showing 30 count package. Label includes barcodes, storage instructions at 20° to 25°C, and mentions each film-coated tablet contains Gabapentin USP 800 mg. Packaged by Contract Pharmacy Services-PA, Warrington, PA.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. It appears to be part of pharmacokinetic or dosing information for the drug Gabapentin.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain scores compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line chart showing mean pain scores over seven weeks for placebo and two dosage groups of Gabapentin (1800 mg/day and 2400 mg/day). The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show decreasing pain scores compared to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistically significant differences noted.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing percentage differences across three studies labeled a, b, and c plotted against daily dose levels (600, 900, 1200, 1800 mg) of Gabapentin. The vertical axis represents the percent difference, while the horizontal axis shows gabapentin daily dose in milligrams.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.